Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 14/20 | 0.84 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 5/20 | 0.48 |
| ▸ | FPR3 | P25089 | 1/20 | 0.43 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4942606 | 0.92 | PTGDR2 (1.00) | PTGDR2ENPP2CCR1 | |
| SCHEMBL4942675 | 0.90 | PTGDR2 (0.89) | PTGDR2ENPP2CCR1FPR3GPR65 | |
| SCHEMBL4607656 | 0.89 | PTGDR2 (0.90) | PTGDR2ENPP2CCR1 | |
| SCHEMBL4944170 | 0.87 | PTGDR2 (0.84) | PTGDR2ENPP2CCR1FPR3GPR65 | |
| SCHEMBL1714418 | 0.87 | PTGDR2 (0.85) | PTGDR2CCR1FPR3GPR65GPR35 | |
| SCHEMBL4609884 | 0.86 | PTGDR2 (0.85) | PTGDR2ENPP2CCR1 | |
| SCHEMBL1714203 | 0.84 | PTGDR2 (0.86) | PTGDR2CCR1FPR3GPR65GPR35 | |
| SCHEMBL1714483 | 0.82 | PTGDR2 (0.86) | PTGDR2CCR1FPR3GPR65GPR35 | |
| SCHEMBL4609428 | 0.81 | PTGDR2 (0.74) | PTGDR2ENPP2CCR1FPR3GPR65 | |
| SCHEMBL4941310 | 0.80 | PTGDR2 (1.00) | PTGDR2ENPP2CCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255150-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
| US-20080255150-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255150-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255150-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | disclosed |
| WO-2007052023-A2 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255150-A1 | Novel Compounds | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | PTGDR2 620/4885ENPP2 159/4885CCR1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.